Literature DB >> 17057169

Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.

R Noecker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17057169      PMCID: PMC1857466          DOI: 10.1136/bjo.2006.098889

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  6 in total

1.  Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.

Authors:  L B Cantor; J Hoop; L Morgan; D Wudunn; Y Catoira
Journal:  Br J Ophthalmol       Date:  2006-07-06       Impact factor: 4.638

2.  Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension.

Authors:  S Gandolfi; S T Simmons; R Sturm; K Chen; A M VanDenburgh
Journal:  Adv Ther       Date:  2001 May-Jun       Impact factor: 3.845

3.  Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.

Authors:  P A Netland; T Landry; E K Sullivan; R Andrew; L Silver; A Weiner; S Mallick; J Dickerson; M V Bergamini; S M Robertson; A A Davis
Journal:  Am J Ophthalmol       Date:  2001-10       Impact factor: 5.258

4.  A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.

Authors:  Richard K Parrish; Paul Palmberg; Wang-Pui Sheu
Journal:  Am J Ophthalmol       Date:  2003-05       Impact factor: 5.258

5.  Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension.

Authors:  Robert J Noecker; Melissa L Earl; Tom Mundorf; James Peace; Robert D Williams
Journal:  Adv Ther       Date:  2003 Mar-Apr       Impact factor: 3.845

6.  A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.

Authors:  Robert S Noecker; Monte S Dirks; Neil T Choplin; Paula Bernstein; Amy L Batoosingh; Scott M Whitcup
Journal:  Am J Ophthalmol       Date:  2003-01       Impact factor: 5.258

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.